Venmax Drugs reported audited standalone FY26 results with revenue surging to ₹8.02 crore from ₹0.81 crore in FY25, driven by operations.
Net profit for the year stood at ₹24.82 lakh, a significant improvement from a net loss of ₹1.05 lakh in the previous financial year.
The company completed a major capital raise by converting 63.44 lakh share warrants into equity, increasing its share capital to ₹11.58 crore.
Auditors PPKG & Co. issued an unmodified opinion on the financial results, confirming compliance with accounting standards and SEBI regulations.